ABSTRACT
Objective:To analyze the value of folate receptor-positive circulating tumor cells (FR +-CTC) in the diagnosis and efficacy evaluation of patients with small cell lung cancer (SCLC). Methods:The data of 59 patients with SCLC and 14 patients with benign pulmonary diseases treated in China-Japan Friendship Hospital from May 2017 to October 2019 were retrospectively analyzed. Folate receptor targeted detection was used to detect the level of FR +-CTC in the blood of SCLC patients. The levels of serum progastrin-releasing peptide (Pro-GRP), neuron-specific enolase (NSE), cytokeratin 19 fragment 21-1 (Cyfra21-1) , and carcinoembryonic antigen (CEA) were detected by using chemiluminescence. The median ( P25, P75) was used as all the detection indexes. Mann-Whitney U test was used for pairwise comparison, Spearman correlation test was used to analyze the correlation between two variables, and receiver operator characteristic (ROC) curve was used to evaluate the diagnostic efficacy. Results:The level of FR +-CTC in 59 patients with SCLC was 11.00 FU/3 ml (7.10 FU/3 ml, 14.50 FU/3 ml), and the positive rate of FR +-CTC in patients with SCLC was 66.10% (30/59); the level of FR +-CTC in 14 patients with benign pulmonary diseases was 6.75 FU/3 ml (5.03 FU/3 ml, 7.85 FU/3 ml), and the positive rate of FR +-CTC in 14 patients with benign pulmonary diseases was 14.29% (2/14). The level of FR +-CTC in patients with SCLC was higher than that in patients with benign pulmonary diseases, and the difference was statistically different ( U = 33.50, P < 0.01). The expression level of FR +-CTC was not related to age, gender and smoking history in SCLC patients (all P>0.05). The expression level of FR +-CTC in patients with extensive-stage was higher than that in patients with limited-stage, and the difference was statistically significant ( P < 0.05). Tumor markers Pro-GRP, NSE, Cyfra21-1 and CEA were compared with FR +-CTC, and the ROC curve was drawn; the results showed that FR +-CTC had better sensitivity (71.2%) and specificity (92.90%) in the diagnosis of SCLC. For SCLC patients who received chemotherapy, the decrease range of FR +-CTC in patients with partial remission and stable disease was greater than that in patients with the progression of disease, and the differences were statistically significant (all P < 0.05). Conclusion:FR +-CTC can assist the diagnosis and disease staging of SCLC. For patients receiving chemotherapy, continuous detection of circulating tumor cells can help to evaluate the efficacy of chemotherapy and provide a reference for the choice of clinical treatment.
ABSTRACT
Objective To investigate the effect of angiotensin convening enzyme inhibitor (ACEI), benazepril, on the clinicohistological changes of normal and adriamycin nephrotic rats. Methods When proteinria was present for 2 weeks after injection of adriamycin, these rats were treated with saline、predsone、 amlodipine and benazepril. Urinary protein excretion was measured in 0, 3rd, 6th week after treatment. Mesangial cell index and mesangial matrix index were assessed in the 6th week. Moreover immunohistochenical stain for type Ⅳ collagen, fibronectin and laminin were performed before and after treatment, and RNA transcription of laminin was evaluated with slit hybridization. Results Proteinuria of benazepril-treated rats was significantly reduced after 6-week treatment compared with those before treatment[ (44 .7 ? 6.0)mg／２４h vs(56.8 ?23 .4)mg/24h. The proliferation of mesangial cells and the synthesis of mesangial matrix were inhibited in the benazepril-treated rats. Similar results were achieved in the predisone-treated rats, but not in amlodipine-treated rats. Conclusion Benazepril can sigificantly reduce the synthesis of mesangial matrix in adriamycin nephrosis rats by inhibiting RNA transcription.